RU2016122957A - Способы применения интерлейкина-10 для лечения заболеваний и расстройств - Google Patents
Способы применения интерлейкина-10 для лечения заболеваний и расстройств Download PDFInfo
- Publication number
- RU2016122957A RU2016122957A RU2016122957A RU2016122957A RU2016122957A RU 2016122957 A RU2016122957 A RU 2016122957A RU 2016122957 A RU2016122957 A RU 2016122957A RU 2016122957 A RU2016122957 A RU 2016122957A RU 2016122957 A RU2016122957 A RU 2016122957A
- Authority
- RU
- Russia
- Prior art keywords
- preparation
- control point
- inhibitor
- immune control
- pharmaceutical composition
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 24
- 102000003814 Interleukin-10 Human genes 0.000 title claims 13
- 108090000174 Interleukin-10 Proteins 0.000 title claims 13
- 208000037765 diseases and disorders Diseases 0.000 title 1
- 229940076144 interleukin-10 Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 claims 8
- 239000003112 inhibitor Substances 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 230000000069 prophylactic effect Effects 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 210000002966 serum Anatomy 0.000 claims 4
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 3
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 102100026882 Alpha-synuclein Human genes 0.000 claims 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 2
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 2
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 101150051188 Adora2a gene Proteins 0.000 claims 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- -1 CTLA Proteins 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 1
- 101001033233 Homo sapiens Interleukin-10 Proteins 0.000 claims 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 229960003697 abatacept Drugs 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 102000052620 human IL10 Human genes 0.000 claims 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 1
- 229960005386 ipilimumab Drugs 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361902702P | 2013-11-11 | 2013-11-11 | |
| US61/902,702 | 2013-11-11 | ||
| PCT/US2014/064620 WO2015070060A1 (en) | 2013-11-11 | 2014-11-07 | Methods of using interleukin-10 for treating diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2016122957A true RU2016122957A (ru) | 2017-12-19 |
Family
ID=53042151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016122957A RU2016122957A (ru) | 2013-11-11 | 2014-11-07 | Способы применения интерлейкина-10 для лечения заболеваний и расстройств |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11413332B2 (enExample) |
| EP (1) | EP3068425B1 (enExample) |
| JP (1) | JP6660297B2 (enExample) |
| KR (1) | KR20160079114A (enExample) |
| CN (2) | CN120242030A (enExample) |
| AU (1) | AU2014346537A1 (enExample) |
| BR (1) | BR112016010166A2 (enExample) |
| CA (1) | CA2928710A1 (enExample) |
| ES (1) | ES2862139T3 (enExample) |
| IL (1) | IL245303A0 (enExample) |
| MX (1) | MX2016005915A (enExample) |
| PH (1) | PH12016500840A1 (enExample) |
| RU (1) | RU2016122957A (enExample) |
| WO (1) | WO2015070060A1 (enExample) |
| ZA (1) | ZA201602839B (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106913865A (zh) | 2013-04-18 | 2017-07-04 | 阿尔莫生物科技股份有限公司 | 使用白细胞介素‑10治疗疾病和病症的方法 |
| EP3010527B1 (en) | 2013-06-17 | 2018-08-08 | Armo Biosciences, Inc. | Method for assessing protein identity and stability |
| HK1226308A1 (zh) | 2013-08-30 | 2017-09-29 | Armo Biosciences, Inc. | 使用白细胞介素-10治疗疾病和病症的方法 |
| EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| US11413332B2 (en) | 2013-11-11 | 2022-08-16 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| US20150259420A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| CN106573072A (zh) | 2014-06-02 | 2017-04-19 | 阿尔莫生物科技股份有限公司 | 降低血清胆固醇的方法 |
| US20170281624A1 (en) | 2014-09-13 | 2017-10-05 | Novartis Ag | Combination therapies of alk inhibitors |
| KR20170068553A (ko) | 2014-10-14 | 2017-06-19 | 아르모 바이오사이언시스 인코포레이티드 | 인터류킨-15 조성물 및 이의 용도 |
| EP3209320B1 (en) | 2014-10-22 | 2023-03-08 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| WO2016126615A1 (en) | 2015-02-03 | 2016-08-11 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| KR20180020141A (ko) | 2015-05-28 | 2018-02-27 | 아르모 바이오사이언시스 인코포레이티드 | 암 치료에 사용되는 peg화된 인터류킨-10 |
| EP3302528A1 (en) * | 2015-05-29 | 2018-04-11 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| JP2018521015A (ja) | 2015-06-01 | 2018-08-02 | メイン・メデイカル・センター・リサーチ・インステイテユート | 免疫チェックポイント阻害薬の治療活性の増強 |
| WO2017025918A1 (en) | 2015-08-11 | 2017-02-16 | Novartis Ag | 5-bromo-2,6-di-(lh-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer |
| CN108025040A (zh) * | 2015-08-25 | 2018-05-11 | 阿尔莫生物科技股份有限公司 | 使用白介素-10治疗疾病和病症的方法 |
| TW202216787A (zh) | 2015-11-18 | 2022-05-01 | 美商默沙東藥廠 | Pd1及／或 lag3結合劑 |
| ES3034582T3 (en) * | 2015-11-18 | 2025-08-20 | Bristol Myers Squibb Co | Treatment of lung cancer using a combination of an anti-pd-1 antibody and an anti-ctla-4 antibody |
| WO2017123557A1 (en) | 2016-01-11 | 2017-07-20 | Armo Biosciences, Inc. | Interleukin-10 in production of antigen-specific cd8+ t cells and methods of use of same |
| WO2017143115A2 (en) | 2016-02-18 | 2017-08-24 | Maine Medical Center Research Institute | Enhancing the therapeutic activity of an immune checkpoint inhibitor |
| US10980797B2 (en) | 2016-03-01 | 2021-04-20 | Corcept Therapeutics Incorporated | Use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors |
| EP4600365A3 (en) * | 2017-02-28 | 2025-12-10 | Genemedicine Co., Ltd. | Anticancer composition comprising tumor-specific oncolytic adenovirus and immune checkpoint inhibitor |
| JP7148539B2 (ja) * | 2017-04-03 | 2022-10-05 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 免疫抱合体 |
| GB201714430D0 (en) | 2017-09-07 | 2017-10-25 | Micol Romain | Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue |
| US20200353050A1 (en) * | 2017-11-10 | 2020-11-12 | Armo Biosciences, Inc. | Compositions and methods of use of interleukin-10 in combination with immune check-point pathway inhibitors |
| JP2021519367A (ja) | 2018-03-28 | 2021-08-10 | ハーバライフ・インターナショナル・オブ・アメリカ・インコーポレイテッド | 多糖のアセチル化 |
| US20210347842A1 (en) * | 2018-06-19 | 2021-11-11 | Eli Lilly And Company | Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy |
| GB201810058D0 (en) * | 2018-06-19 | 2018-08-08 | Cytovation As | Combination therapy using a peptide |
| US11389432B2 (en) | 2018-12-19 | 2022-07-19 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| CN113347990A (zh) * | 2018-12-21 | 2021-09-03 | 西北大学 | 膜联蛋白在预防和治疗肌膜损伤中的用途 |
| US12006345B2 (en) | 2019-02-21 | 2024-06-11 | Xencor, Inc. | Untargeted and targeted IL-10 Fc-fusion proteins |
| BR102019007044A2 (pt) | 2019-04-05 | 2021-12-28 | Universidade Federal de Uberlândia | Peptídeos sintéticos com afinidade ao receptor de interleucina-10, composição farmacêutica e uso dos mesmos como imunomuduladores no tratamento de doenças autoimunes, inflamatórias ou alérgicas |
| WO2020249003A1 (en) * | 2019-06-10 | 2020-12-17 | Apollomics Inc. (Hangzhou) | Antibody-interleukin fusion protein and methods of use |
| KR20220066056A (ko) | 2019-08-16 | 2022-05-23 | 어플라이드 몰레큘라 트랜스포트 인크. | 조성물, 제형, 및 인터루킨 제조 및 정제 |
| IL298007A (en) | 2020-05-12 | 2023-01-01 | Regeneron Pharma | Novel il10 agonists and methods of use thereof |
| US20240190934A1 (en) * | 2022-11-28 | 2024-06-13 | Elixiron Immunotherapeutics (hong Kong) Limited | Engineered interleukin-10 and fusion proteins thereof |
Family Cites Families (133)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1202840A (en) | 1985-06-10 | 1986-04-08 | Jonathan R. Kleinsasser | Combination wet and dry feeder for animals |
| JPS63152393A (ja) | 1986-07-03 | 1988-06-24 | Takeda Chem Ind Ltd | グリコシル誘導体 |
| US5714585A (en) | 1987-10-26 | 1998-02-03 | Sterling Winthrop, Inc. | Antibodies that are immunoreactive with interleukin-7 |
| US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
| US5032396A (en) | 1989-02-17 | 1991-07-16 | Immunex Corporation | IL-7 to stimulate platelet production |
| US6217857B1 (en) | 1989-06-28 | 2001-04-17 | Schering Corporation | Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof |
| US5231012A (en) | 1989-06-28 | 1993-07-27 | Schering Corporation | Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10) |
| US5229115A (en) | 1990-07-26 | 1993-07-20 | Immunex Corporation | Adoptive immunotherapy with interleukin-7 |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| KR100207766B1 (ko) | 1991-01-16 | 1999-07-15 | 둘락 노먼 씨. | 신생물 질환 치료용 인터루킨-10 조성물 |
| ZA92304B (en) | 1991-01-16 | 1992-09-30 | Schering Corp | Use of interleukin-10 in adoptive immunotherapy of cancer |
| US5624823A (en) | 1991-11-22 | 1997-04-29 | The General Hospital Corporation | DNA encoding procine interleukin-10 |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| EP0681589A1 (en) | 1993-02-01 | 1995-11-15 | Université Libre de Bruxelles | Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10 |
| US5328989A (en) | 1993-03-05 | 1994-07-12 | Schering-Plough | Purification of human interleukin-10 from a cell culture medium |
| US5552303A (en) | 1993-03-08 | 1996-09-03 | Immunex Corporation | DNA encoding epithelium-derived T-cell factor |
| WO1994022473A1 (en) | 1993-04-01 | 1994-10-13 | University Of Washington | Use of interleukin 7 to improve vaccine potency |
| US5665345A (en) | 1993-05-24 | 1997-09-09 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of inhibiting viral replication using IL-10 |
| HUT73463A (en) | 1993-07-26 | 1996-08-28 | Schering Corp | Agonists and antagonists of human interleukin-10 |
| GB9317618D0 (en) | 1993-08-24 | 1993-10-06 | Royal Free Hosp School Med | Polymer modifications |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5951974A (en) | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
| FI962813A0 (fi) | 1994-01-20 | 1996-07-11 | Schering Corp | IL-10:n käyttö perifeerisen veren yksitumaisten solujen sytolyyttisen aktiivisuuden stimuloimiseen |
| US5696234A (en) | 1994-08-01 | 1997-12-09 | Schering Corporation | Muteins of mammalian cytokine interleukin-13 |
| US5650234A (en) | 1994-09-09 | 1997-07-22 | Surface Engineering Technologies, Division Of Innerdyne, Inc. | Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US6410008B1 (en) | 1994-12-12 | 2002-06-25 | Beth Israel Hospital Association | Chimeric IL-10 proteins and uses thereof |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5866134A (en) | 1995-03-24 | 1999-02-02 | Schering Corporation | Method for enhancing the antibody response to specific antigens with Interleukin-10 |
| US5770190A (en) | 1995-07-14 | 1998-06-23 | Schering Corporation | Method of treatment of acute leukemia with inteleukin-10 |
| GB2304047A (en) | 1995-08-09 | 1997-03-12 | Univ Manchester | Pharmaceutical compositions containing cytokines |
| US5744451A (en) | 1995-09-12 | 1998-04-28 | Warner-Lambert Company | N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US5759859A (en) | 1996-07-15 | 1998-06-02 | United States Of America As Represented By The Secretary Of The Army | Sensor and method for detecting trace underground energetic materials |
| US5945097A (en) | 1996-09-06 | 1999-08-31 | Schering Corporation | Method for lowering cholesterol levels with interleukin-10 |
| US5989867A (en) | 1996-09-23 | 1999-11-23 | Knappe; Andrea | DNA encoding IL-10-like homologue; related reagents |
| US6660258B1 (en) | 1997-05-09 | 2003-12-09 | Pharma Pacific Pty Ltd | Oromucosal cytokine compositions and uses thereof |
| ES2297889T3 (es) | 1997-07-14 | 2008-05-01 | Bolder Biotechnology, Inc. | Derivados de hormona de crecimiento y proteinas relacionadas. |
| US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
| AU755051B2 (en) | 1998-01-07 | 2002-12-05 | Debio Recherche Pharmaceutique S.A. | Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom |
| US6428985B1 (en) | 1998-12-02 | 2002-08-06 | The Regents Of The University Of Michigan | Immunosuppressive structural definition of IL-10 |
| JP2002532556A (ja) | 1998-12-22 | 2002-10-02 | シェリング・コーポレーション | Ｃ型肝炎ウイルス感染のインターロイキン−１０での処置 |
| US7666400B2 (en) | 2005-04-06 | 2010-02-23 | Ibc Pharmaceuticals, Inc. | PEGylation by the dock and lock (DNL) technique |
| AU5827000A (en) | 1999-07-16 | 2001-02-05 | Maria Teresa Bejarano | Viral il-10 uses |
| US6989377B2 (en) | 1999-12-21 | 2006-01-24 | Wisconsin Alumni Research Foundation | Treating vitamin D responsive diseases |
| US20030186386A1 (en) | 2000-02-11 | 2003-10-02 | Hansen Christian Karsten | Interleukin 10 |
| AU2001231532A1 (en) | 2000-02-11 | 2001-08-20 | Maxygen Aps | Improved interleukin 10 |
| EP2295450B1 (en) | 2000-09-29 | 2015-01-28 | Merck Sharp & Dohme Corp. | Pegylated interleukin-10 |
| JP2002142770A (ja) | 2000-11-08 | 2002-05-21 | Dnavec Research Inc | 循環系への遺伝子送達用パラミクソウイルスベクター |
| US6838452B2 (en) | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| EP1234583A1 (en) | 2001-02-23 | 2002-08-28 | F. Hoffmann-La Roche Ag | PEG-conjugates of HGF-NK4 |
| WO2002085300A2 (en) | 2001-04-23 | 2002-10-31 | The Regents Of The University Of California | Methods of using interleukin-7 to modulate physiological processes in mammalian pulmonary fibroblasts |
| GB0212648D0 (en) | 2002-05-31 | 2002-07-10 | Immunoclin Lab Ltd | Treatment with cytokines |
| EP1391513A1 (en) | 2002-08-08 | 2004-02-25 | Cytheris | IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof |
| ES2343518T3 (es) | 2002-09-09 | 2010-08-03 | Hanall Biopharma Co., Ltd. | Polipeptidos interferon alfa modificados resistentes a proteasas. |
| AU2003280315A1 (en) | 2002-11-14 | 2004-06-03 | Maxygen, Inc. | Conjugates of interleukin-10 and polymers |
| ES2312820T3 (es) | 2002-11-29 | 2009-03-01 | Maria Grazia Roncarolo | Paramicina e il-10 para el tratamiento de enfermedades autoinmunes. |
| WO2004056850A2 (en) | 2002-12-19 | 2004-07-08 | Vib Vzw | Mutant proteins showing increased secretion |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| KR101162908B1 (ko) | 2002-12-26 | 2012-07-06 | 마운틴 뷰 파마슈티컬즈, 인크. | 수용체-결합 활성이 보존된, 사이토카인, 케모카인,성장인자, 폴리펩티드 호르몬 및 이들의 길항제의 중합체접합체 |
| AU2004217894B2 (en) | 2003-03-03 | 2010-07-15 | Bracco International B.V. | Peptides that specifically bind HGF receptor (cMet) and uses thereof |
| EP1613274B1 (en) | 2003-04-15 | 2010-03-03 | GlaxoSmithKline LLC | Human il-18 substitution mutants and their conjugates |
| US7261882B2 (en) | 2003-06-23 | 2007-08-28 | Reagents Of The University Of Colorado | Methods for treating neuropathic pain by administering IL-10 polypeptides |
| WO2005033307A1 (ja) | 2003-09-30 | 2005-04-14 | Kyowa Hakko Kogyo Co., Ltd. | 新規のリフォールディング方法およびその方法によって得られたタンパク質 |
| WO2005052159A1 (en) | 2003-11-28 | 2005-06-09 | The University Of Sydney | Latent phase viral interleukin-10-(vii-10) and uses thereof |
| PL1699822T3 (pl) | 2003-12-30 | 2008-08-29 | Merck Patent Gmbh | Białka fuzyjne IL-7 z częściami przeciwciała, ich otrzymywanie oraz ich zastosowanie |
| US20060078942A1 (en) | 2004-03-10 | 2006-04-13 | Pepgen Corporation | Method of treatment using interferon-tau |
| EP1725589A1 (en) | 2004-03-11 | 2006-11-29 | Fresenius Kabi Deutschland GmbH | Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination |
| HUE026284T2 (en) | 2004-08-10 | 2016-06-28 | Genzyme Corp | Oligonucleotides for use in modulating lipoprotein and cholesterol levels in humans |
| US20060046961A1 (en) | 2004-09-02 | 2006-03-02 | Mckay William F | Controlled and directed local delivery of anti-inflammatory compositions |
| CN100334112C (zh) | 2004-10-15 | 2007-08-29 | 上海海欣生物技术有限公司 | 人白细胞介素15与Fc融合蛋白 |
| CA2591297C (en) | 2004-12-09 | 2015-01-13 | Stephen D. Gillies | Il-7 variants with reduced immunogenicity |
| GB0500643D0 (en) | 2005-01-13 | 2005-02-23 | Renovo Ltd | Medicaments |
| WO2006094530A1 (en) | 2005-03-11 | 2006-09-14 | Siegfried Ltd. | Di-polymer protein conjugates and processes for their preparation |
| UY29460A1 (es) | 2005-04-08 | 2006-11-30 | Noxxon Pharma Ag | Acidos nucleicos de union a ghrelin |
| EP1901769A2 (en) | 2005-05-02 | 2008-03-26 | Avigen, Inc. | Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease |
| AU2006244885B2 (en) * | 2005-05-09 | 2011-03-31 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| DE602006011311D1 (de) | 2005-05-31 | 2010-02-04 | Univ Colorado | Il-10 mutante |
| EP1910513B1 (en) | 2005-07-01 | 2016-08-10 | John Schrader | Methods of isolating antibody secreting cells from blood samples of immunized animals and generating monoclonal antibodies from said antibody secreting cells. |
| EP1746161A1 (en) | 2005-07-20 | 2007-01-24 | Cytheris | Glycosylated IL-7, preparation and uses |
| DK1931704T3 (da) | 2005-10-04 | 2011-03-14 | Zymogenetics L L C | Frembringelse og rensning af IL-29 |
| WO2007061657A2 (en) | 2005-11-14 | 2007-05-31 | The Brigham & Women's Hospital, Inc. | Interleukin-10 compositions for the treatment of adenocarcinomas |
| US7868139B2 (en) | 2006-01-24 | 2011-01-11 | Uab Research Foundation | Compositions and methods for the identification and treatment of immune-mediated inflammatory diseases |
| US7662965B2 (en) * | 2006-01-26 | 2010-02-16 | Cornerstone Therapeutics, Inc. | Anabaseine derivatives, pharmaceutical compositions and method of use thereof |
| US20080081031A1 (en) | 2006-09-28 | 2008-04-03 | Schering Corporation | Use of Pegylated IL-10 to Treat Cancer |
| WO2008041953A2 (en) | 2006-10-05 | 2008-04-10 | Agency For Science, Technology And Research | Dengue diagnosis and treatment |
| JP5220025B2 (ja) | 2006-12-04 | 2013-06-26 | プロメディオール， インコーポレイテッド | 線維症疾患を処置するための併用療法 |
| KR101775929B1 (ko) | 2007-01-19 | 2017-09-07 | 카이 파마슈티컬즈 | 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형 |
| US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| DE08786222T1 (de) | 2007-07-31 | 2010-11-25 | Affibody Ab | Neue albuminbindende zusammensetzungen, verfahren und anwendungen |
| WO2009036568A1 (en) | 2007-09-19 | 2009-03-26 | University Health Network | Methods and compositions for treating tumors and viral infections |
| WO2009052454A2 (en) | 2007-10-19 | 2009-04-23 | University Of California | Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss |
| CA2706700A1 (en) | 2007-11-08 | 2009-05-14 | Cytimmune Sciences, Inc. | Compositions and methods for generating antibodies |
| GB0724231D0 (en) | 2007-12-12 | 2008-01-30 | Renono Ltd | Methods for inhibiting scarring |
| MX2010012579A (es) | 2008-05-29 | 2010-12-20 | Squibb Bristol Myers Co | Metodos para predecir respuesta de pacientes a modulacion de la via co-estimuladora. |
| WO2010022227A1 (en) | 2008-08-20 | 2010-02-25 | Schering Corporation | Methods for monitoring il-10 therapy |
| KR20110112301A (ko) | 2008-11-18 | 2011-10-12 | 메리맥 파마슈티컬즈, 인크. | 인간 혈청 알부민 링커 및 그 콘쥬게이트 |
| EP2379115B1 (en) | 2008-12-17 | 2017-10-25 | Merck Sharp & Dohme Corp. | Mono- and di-peg il-10 production; and uses |
| EP3381937A3 (en) * | 2009-08-13 | 2018-10-31 | The Johns Hopkins University | Methods of modulating immune function |
| US10464987B2 (en) | 2009-10-06 | 2019-11-05 | Abbvie Inc. | Human single-chain T cell receptors |
| AU2010308030B2 (en) | 2009-10-12 | 2014-05-29 | Pfizer Inc. | Cancer treatment |
| GB2488077A (en) | 2009-10-30 | 2012-08-15 | Novozymes Biopharma Dk As | Albumin variants |
| KR101802261B1 (ko) | 2009-11-30 | 2017-11-28 | 바이오테스트 아게 | 전신 홍반성 낭창을 치료하기 위한 인간화된 항-ｉｌ-10 항체 |
| DK2542590T4 (da) * | 2010-03-05 | 2020-07-13 | Univ Johns Hopkins | Sammensætninger og fremgangsmåde til målrettede immunomodulatoriske antistof-fer og fusionproteiner |
| WO2011159878A1 (en) | 2010-06-16 | 2011-12-22 | Abbott Laboratories | Comparison of protein samples |
| US9163087B2 (en) | 2010-06-18 | 2015-10-20 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions |
| TR201809437T4 (tr) | 2010-07-09 | 2018-07-23 | Affibody Ab | Polipeptitler. |
| US8759617B2 (en) | 2010-09-21 | 2014-06-24 | National Institute Of Agrobiological Sciences | Method for extraction and purification of recombinant proteins from transgenic plants |
| CN103547590B (zh) | 2010-09-28 | 2017-11-28 | 埃格里昂制药股份有限公司 | 高度可溶性瘦蛋白 |
| WO2012050923A2 (en) | 2010-09-28 | 2012-04-19 | Amylin Pharmaceuticals, Inc. | Engineered polypeptides having enhanced duration of action |
| US8895536B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating chronic inflammation and inflammatory diseases |
| BR112013024395B1 (pt) | 2011-03-23 | 2021-10-26 | Fred Hutchinson Cancer Research Center | Composições adotivas de imunoterapia celular e método para fabricação da dita composição |
| CN102145178B (zh) | 2011-04-15 | 2012-09-26 | 北京凯因科技股份有限公司 | Peg化白介素15 |
| EP2537933A1 (en) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
| US20140242081A1 (en) * | 2011-07-18 | 2014-08-28 | Micromet Ag | Dosing regimens for treatment of cea-expressing cancers |
| WO2013059323A1 (en) | 2011-10-18 | 2013-04-25 | Prolynx Llc | Peg conjugates of exenatide |
| US10391126B2 (en) | 2011-11-18 | 2019-08-27 | Board Of Regents, The University Of Texas System | CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA |
| JP2015506373A (ja) | 2012-01-26 | 2015-03-02 | アムジエン・インコーポレーテツド | 成長分化因子１５（ｇｄｆ−１５）ポリペプチド |
| HK1205746A1 (en) | 2012-02-29 | 2015-12-24 | Ambrx, Inc. | Interleukin-10 polypeptide conjugates and their uses |
| US20150118244A1 (en) | 2012-05-10 | 2015-04-30 | Bristol-Myers Squibb Company | Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients |
| DK2947111T3 (en) | 2013-01-17 | 2018-05-07 | Xiamen Sinopeg Biotech Co Ltd | MONOFUNCTIONAL BRANCHED POLYETHYLENE LYCOL AND BIORELATED SUBSTANCE MODIFIED BY SAME |
| CN106913865A (zh) | 2013-04-18 | 2017-07-04 | 阿尔莫生物科技股份有限公司 | 使用白细胞介素‑10治疗疾病和病症的方法 |
| JP2016526014A (ja) | 2013-04-24 | 2016-09-01 | アルモ・バイオサイエンシーズ・インコーポレイテッド | インターロイキン−１０組成物及びその使用 |
| EP3010527B1 (en) | 2013-06-17 | 2018-08-08 | Armo Biosciences, Inc. | Method for assessing protein identity and stability |
| HK1226308A1 (zh) | 2013-08-30 | 2017-09-29 | Armo Biosciences, Inc. | 使用白细胞介素-10治疗疾病和病症的方法 |
| US11413332B2 (en) | 2013-11-11 | 2022-08-16 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| US20160375101A1 (en) | 2014-01-15 | 2016-12-29 | Armo Biosciences, Inc. | Methods of Using Interleukin-10 for Treating Diseases and Disorders |
| EP4303229A3 (en) | 2014-01-21 | 2024-04-17 | Novartis AG | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
| MA39711A (fr) | 2014-04-03 | 2015-10-08 | Nektar Therapeutics | Conjugués d'une fraction d'il-15 et d'un polymère |
| CN106573072A (zh) | 2014-06-02 | 2017-04-19 | 阿尔莫生物科技股份有限公司 | 降低血清胆固醇的方法 |
| EP3285799A4 (en) | 2015-03-11 | 2018-08-08 | Nektar Therapeutics | Conjugates of an il-7 moiety and an polymer |
| KR20180020141A (ko) | 2015-05-28 | 2018-02-27 | 아르모 바이오사이언시스 인코포레이티드 | 암 치료에 사용되는 peg화된 인터류킨-10 |
-
2014
- 2014-11-07 US US15/031,651 patent/US11413332B2/en active Active
- 2014-11-07 WO PCT/US2014/064620 patent/WO2015070060A1/en not_active Ceased
- 2014-11-07 CN CN202510416932.2A patent/CN120242030A/zh active Pending
- 2014-11-07 KR KR1020167015158A patent/KR20160079114A/ko not_active Withdrawn
- 2014-11-07 MX MX2016005915A patent/MX2016005915A/es unknown
- 2014-11-07 JP JP2016528896A patent/JP6660297B2/ja active Active
- 2014-11-07 EP EP14860137.0A patent/EP3068425B1/en active Active
- 2014-11-07 AU AU2014346537A patent/AU2014346537A1/en not_active Abandoned
- 2014-11-07 CA CA2928710A patent/CA2928710A1/en not_active Abandoned
- 2014-11-07 CN CN201480068159.5A patent/CN105848674A/zh active Pending
- 2014-11-07 ES ES14860137T patent/ES2862139T3/es active Active
- 2014-11-07 BR BR112016010166A patent/BR112016010166A2/pt not_active IP Right Cessation
- 2014-11-07 RU RU2016122957A patent/RU2016122957A/ru unknown
-
2016
- 2016-04-25 ZA ZA2016/02839A patent/ZA201602839B/en unknown
- 2016-04-25 IL IL245303A patent/IL245303A0/en unknown
- 2016-05-05 PH PH12016500840A patent/PH12016500840A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12016500840A1 (en) | 2016-07-11 |
| EP3068425B1 (en) | 2021-01-27 |
| JP6660297B2 (ja) | 2020-03-11 |
| WO2015070060A1 (en) | 2015-05-14 |
| ZA201602839B (en) | 2017-09-27 |
| EP3068425A4 (en) | 2017-05-17 |
| CA2928710A1 (en) | 2015-05-14 |
| IL245303A0 (en) | 2016-06-30 |
| KR20160079114A (ko) | 2016-07-05 |
| CN105848674A (zh) | 2016-08-10 |
| ES2862139T3 (es) | 2021-10-07 |
| EP3068425A1 (en) | 2016-09-21 |
| MX2016005915A (es) | 2016-12-16 |
| US11413332B2 (en) | 2022-08-16 |
| JP2016537340A (ja) | 2016-12-01 |
| BR112016010166A2 (pt) | 2017-12-05 |
| AU2014346537A1 (en) | 2016-05-19 |
| US20160243196A1 (en) | 2016-08-25 |
| CN120242030A (zh) | 2025-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016122957A (ru) | Способы применения интерлейкина-10 для лечения заболеваний и расстройств | |
| JP7253210B2 (ja) | Ｗｔ１抗原ペプチドおよび免疫調節剤の併用 | |
| JP2016537340A5 (enExample) | ||
| US12201686B2 (en) | Compositions including a therapeutic antibodies and/or a checkpoint inhibitor and an integrin activating compound | |
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| JP2016527286A5 (enExample) | ||
| JP2017533201A5 (enExample) | ||
| JP7209986B2 (ja) | 癌を処置するための医薬組成物 | |
| US20230190865A1 (en) | VIP Antagonists and Uses in Treating Cancer | |
| JP7281795B2 (ja) | 膵炎および疼痛をデス受容体アゴニストで処置するための組成物および方法 | |
| MX2022002293A (es) | Péptidos recombinantes inmunotolerantes similares a la elastina y métodos de uso. | |
| TW201828984A (zh) | 使用介白素-17(il-17)拮抗劑治療痤瘡的方法 | |
| RU2818832C2 (ru) | Композиции и способы для повышения веса тела и сухой мышечной массы с применением антагонистов рецептора лептина, gdf8 и активина а | |
| JP2024509911A (ja) | 疾患の治療のための方法及び組成物 | |
| JP2016509590A (ja) | 加齢に伴う障害の治療のための組換え７型コラーゲンの投与 | |
| NZ747504B2 (en) | Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies | |
| NZ787392B2 (en) | Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 | |
| RU2020134794A (ru) | Способы лечения хронической спонтанной крапивницы с применением лигелизумаба | |
| NZ747504A (en) | Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies | |
| HK1250213B (en) | Combination of wt1 antigen peptide, immunomodulator and wt1 helper peptide | |
| EA041148B1 (ru) | Композиции и способы для лечения панкреатита и боли с применением агонистов рецептора смерти |